Lung Cancer Trials Ask AI to find trials
RecruitingNot applicableNCT06080061
Official study title

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Study summary

The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedHypofractionated accelerated radiation therapy

The study team can explain what participation involves.

Who it may be forLocally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 7, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Interventional

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?Stanford University

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Not applicable
Sponsor
Stanford University
Interventions being studied
Radiation: Hypofractionated accelerated radiation therapy
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Locally advanced→
Treatment approach
Radiation therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologically or cytologically documented malignancy of the thorax including but not limited to non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy
  • ECOG performance status of 0-2
  • PET/CT or CT Imaging of Thorax
  • Age ≥ 18 years old
  • Ability to understand and the willingness to personally sign the written IRB approved informed consent document
  • Estimated life expectancy of 12 weeks or longer
Reasons someone may not be able to joinExclusion criteria
  • Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist
  • Age \< 18 years old
  • Diagnosis of interstitial pulmonary fibrosis
  • Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Stanford UniversityPalo Alto, California
  • Stanford Cancer Center South BaySan Jose, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 7, 2026. Always confirm current availability with the study team.

View original record ↗